Literature DB >> 29291140

Mesenchymal Stem Cell Soluble Mediators and Cystic Fibrosis.

Morgan T Sutton1,2,3,4,5,6, David Fletcher1, Nicole Episalla1,7, Lauren Auster1,7, Sukhmani Kaur1,5, Mary Chandler Gwin1,6, Michael Folz4, Dante Velasquez1,2, Varun Roy1,3, Rolf van Heeckeren1, Donald P Lennon7,8, Arnold I Caplan7,8, Tracey L Bonfield1,2,3,8.   

Abstract

Human Mesenchymal stem cells (hMSCs) secrete products (supernatants) that are anti-inflammatory and antimicrobial. We have previously shown that hMSCs decrease inflammation and Pseudomonas aeruginosa infection in the in vivo murine model of Cystic Fibrosis (CF). Cystic Fibrosis (CF) is a genetic disease in which pulmonary infection and inflammation becomes the major cause of morbidity and mortality. Our studies focus on determining how MSCs contribute to improved outcomes in the CF mouse model centering on how the MSCs impact the inflammatory response to pathogenic organisms. We hypothesize that MSCs secrete products that are anti-inflammatory in scenarios of chronic pulmonary infections using the murine model of infection and inflammation with a specific interest in Pseudomonas aeruginosa (gram negative). Further, our studies will identify whether the MSCs are impacting this inflammatory response through the regulation of peroxisome proliferator activator receptor gamma (PPARγ) which aides in decreasing inflammation.

Entities:  

Keywords:  Anti-Inflammation; Anti-Inflammatory Cytokines; Chemokines; Cytokines; Mesenchymal stem cells; PPARγ; chemotaxis; cystic fibrosis

Year:  2017        PMID: 29291140      PMCID: PMC5747256          DOI: 10.4172/2157-7633.1000400

Source DB:  PubMed          Journal:  J Stem Cell Res Ther


  47 in total

Review 1.  Chemokines: multiple levels of leukocyte migration control.

Authors:  Bernhard Moser; Marlene Wolf; Alfred Walz; Pius Loetscher
Journal:  Trends Immunol       Date:  2004-02       Impact factor: 16.687

2.  Action at a distance: systemically administered adult stem/progenitor cells (MSCs) reduce inflammatory damage to the cornea without engraftment and primarily by secretion of TNF-α stimulated gene/protein 6.

Authors:  Gavin W Roddy; Joo Youn Oh; Ryang Hwa Lee; Thomas J Bartosh; Joni Ylostalo; Katie Coble; Robert H Rosa; Darwin J Prockop
Journal:  Stem Cells       Date:  2011-10       Impact factor: 6.277

3.  Immunomodulatory properties of mesenchymal stem cells derived from dental pulp and dental follicle are susceptible to activation by toll-like receptor agonists.

Authors:  Sergej Tomic; Jelena Djokic; Sasa Vasilijic; Dragana Vucevic; Vera Todorovic; Gordana Supic; Miodrag Colic
Journal:  Stem Cells Dev       Date:  2011-02-10       Impact factor: 3.272

Review 4.  Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence.

Authors:  Kavitha Kotha; John P Clancy
Journal:  Ther Adv Respir Dis       Date:  2013-09-03       Impact factor: 4.031

Review 5.  Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation.

Authors:  Maria G Belvisi; David J Hele; Mark A Birrell
Journal:  Eur J Pharmacol       Date:  2006-02-03       Impact factor: 4.432

Review 6.  The role of PPARs in inflammation and immunity.

Authors:  Robert B Clark
Journal:  J Leukoc Biol       Date:  2002-03       Impact factor: 4.962

7.  Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis.

Authors:  Elliott C Dasenbrook; William Checkley; Christian A Merlo; Michael W Konstan; Noah Lechtzin; Michael P Boyle
Journal:  JAMA       Date:  2010-06-16       Impact factor: 56.272

8.  PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages.

Authors:  John S Welch; Mercedes Ricote; Taro E Akiyama; Frank J Gonzalez; Christopher K Glass
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-09       Impact factor: 11.205

Review 9.  Emerging roles of PPARs in inflammation and immunity.

Authors:  Raymond A Daynes; Dallas C Jones
Journal:  Nat Rev Immunol       Date:  2002-10       Impact factor: 53.106

10.  Defining human mesenchymal stem cell efficacy in vivo.

Authors:  Tracey L Bonfield; Mary T Nolan Koloze; Donald P Lennon; Arnold I Caplan
Journal:  J Inflamm (Lond)       Date:  2010-10-25       Impact factor: 4.981

View more
  8 in total

1.  Human Amniotic Mesenchymal Stem Cells and Fibroblasts Accelerate Wound Repair of Cystic Fibrosis Epithelium.

Authors:  Elisa Beccia; Valeria Daniello; Onofrio Laselva; Giorgia Leccese; Michele Mangiacotti; Sante Di Gioia; Gianfranco La Bella; Lorenzo Guerra; Maria Matteo; Antonella Angiolillo; Massimo Conese
Journal:  Life (Basel)       Date:  2022-05-19

2.  Enhancing Cystic Fibrosis Immune Regulation.

Authors:  Anna M van Heeckeren; Morgan T Sutton; David R Fletcher; Craig A Hodges; Arnold I Caplan; Tracey L Bonfield
Journal:  Front Pharmacol       Date:  2021-05-13       Impact factor: 5.810

3.  Donor-defined mesenchymal stem cell antimicrobial potency against nontuberculous mycobacterium.

Authors:  Tracey L Bonfield; Morgan T Sutton; David R Fletcher; Michael A Folz; Vaishnavi Ragavapuram; Rodrigo A Somoza; Arnold I Caplan
Journal:  Stem Cells Transl Med       Date:  2021-05-04       Impact factor: 6.940

4.  Antibacterial activity of human mesenchymal stem cells mediated directly by constitutively secreted factors and indirectly by activation of innate immune effector cells.

Authors:  Lyndah Chow; Valerie Johnson; Renata Impastato; Jonathan Coy; Alyssa Strumpf; Steven Dow
Journal:  Stem Cells Transl Med       Date:  2019-11-08       Impact factor: 6.940

Review 5.  Cell-Based Therapeutic Approaches for Cystic Fibrosis.

Authors:  Pascal Duchesneau; Thomas K Waddell; Golnaz Karoubi
Journal:  Int J Mol Sci       Date:  2020-07-23       Impact factor: 5.923

Review 6.  Potential of Mesenchymal Stem Cell-Derived Exosomes as a Novel Treatment for Female Infertility Caused by Bacterial Infections.

Authors:  Marzieh Zohrabi; Laleh Dehghan Marvast; Mahin Izadi; Seyed Alireza Mousavi; Behrouz Aflatoonian
Journal:  Front Microbiol       Date:  2022-01-27       Impact factor: 5.640

Review 7.  Lights and Shadows in the Use of Mesenchymal Stem Cells in Lung Inflammation, a Poorly Investigated Topic in Cystic Fibrosis.

Authors:  Anna Caretti; Valeria Peli; Michela Colombo; Aida Zulueta
Journal:  Cells       Date:  2019-12-19       Impact factor: 6.600

8.  Mesenchymal Stem Cells Attenuates TGF-β1-Induced EMT by Increasing HGF Expression in HK-2 Cells.

Authors:  Jun-Jun Wei; Li Tang; Liang-Liang Chen; Zhen-Hua Xie; Yu Ren; Hong-Gang Qi; Jiang-Yong Lou; Guo-Bin Weng; Shu-Wei Zhang
Journal:  Iran J Public Health       Date:  2021-05       Impact factor: 1.429

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.